Press release
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus
DelveInsight's "Dry Age-Related Macular Degeneration (Dry-AMD) - Pipeline Insight, 2026" report provides comprehensive insights about 70+ companies developing over 80 pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the Dry-AMD pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Dry Age-Related Macular Degeneration treatment landscape. Learn more about the evolving Dry-AMD pipeline today @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
*
On April 13, 2026, Sylentis, S.A. announced a clinical trial to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops in patients with macular degeneration.
*
In January 2026, Ocugen reported that its modifier gene therapy OCU-410 slowed the growth of atrophic lesions (areas of cell death) by 46% in a Phase 1/2 clinical trial.
*
Topline data from the global Phase III ReNEW trial evaluating daily subcutaneous dosing of elamipretide to slow photoreceptor loss in dry AMD are expected in 2026.
*
Pivotal Phase 3 trials-ATMOSPHERE and ASCENT-for Surabgene Lomparvovec (ABBV-RGX-314), an investigational one-time gene therapy, are currently ongoing with topline data expected in 2026.
*
Preliminary data from the Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for Best vitelliform macular dystrophy with implications for dry AMD research, are expected during the first quarter of 2026.
*
Dry Age-Related Macular Degeneration is a leading cause of irreversible blindness, affecting approximately 170 million people globally, with geographic atrophy representing its advanced stage.
*
In 2023, the United States accounted for the highest prevalent cases of dry AMD among the 7MM, with around 21 million cases expected to increase by 2034.
*
DelveInsight's Dry-AMD Pipeline Insight report depicts a robust clinical development space with 70+ active players advancing over 80 pipeline therapies across multiple stages.
*
The leading Dry Age-Related Macular Degeneration companies include Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus Pharmaceuticals, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and others.
Download for updates and the latest revolution in Dry-AMD care @ Dry Age-Related Macular Degeneration Market Insight, Epidemiology And Market Forecast [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Dry Age-Related Macular Degeneration Emerging Drugs Profile
Tinlarebant (LBS-008): Belite Bio
Tinlarebant is a novel oral therapy being independently developed by Belite Bio for the treatment of dry Age-Related Macular Degeneration and Stargardt disease. It is designed to reduce the accumulation of toxins in the eye that lead to retinal degeneration. Currently, Tinlarebant is in Phase III clinical evaluation, representing one of the most advanced oral candidates in the Dry-AMD pipeline.
Elamipretide: Stealth BioTherapeutics
Elamipretide is a potential first-in-class mitochondrial stabilizing agent currently being evaluated in late-stage development. It is the only class of therapy to have demonstrated a potential to improve low luminance visual acuity (LLVA) in dry AMD patients. Currently, elamipretide is the subject of the global Phase III ReNEW trial, evaluating daily subcutaneous dosing to slow photoreceptor loss, with topline data expected in 2026.
OCU-410: Ocugen
OCU-410 is a modifier gene therapy designed to slow the progression of atrophic lesions associated with geographic atrophy secondary to dry AMD. It is administered via a single sub-retinal injection and targets multiple pathological pathways, including lipid metabolism, inflammation, oxidative stress, and complement activation. Currently, OCU-410 is in Phase 1/2 clinical trial evaluation, with recent interim data showing a significant 46% reduction in lesion growth.
For more information on the Dry Age-Related Macular Degeneration Emerging Drugs Profile, download DelveInsight's comprehensive Dry Age-Related Macular Degeneration Pipeline Insight report [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Dry Age-Related Macular Degeneration Pipeline Report Provides
*
Detailed insights about companies developing therapies for Dry Age-Related Macular Degeneration, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Dry-AMD treatment.
*
Dry-AMD companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Dry-AMD drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Dry-AMD market.
Learn more about Dry Age-Related Macular Degeneration drug opportunities in our comprehensive Dry-AMD pipeline report @ Dry Age-Related Macular Degeneration Unmet Needs [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Dry Age-Related Macular Degeneration Companies and Competitive Landscape
There are 70+ key companies, including Belite Bio, Alkeus Pharmaceuticals, Stealth BioTherapeutics, Ocugen, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and Novartis, developing therapies for Dry Age-Related Macular Degeneration. Multiple candidates are advancing through late-stage Phase III trials, reflecting a significant change in the upcoming forecast period.
DelveInsight's Dry Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Dry Age-Related Macular Degeneration products have been categorized under various Molecule types such as:
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Discover the latest advancements in Dry Age-Related Macular Degeneration treatment by visiting our website. Stay informed @ Dry Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Dry Age-Related Macular Degeneration Pipeline Report
*
Coverage: Global
*
Dry Age-Related Macular Degeneration Companies: Belite Bio, Alkeus Pharmaceuticals, Stealth BioTherapeutics, Ocugen, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Roche, and others.
*
Dry Age-Related Macular Degeneration Therapies: Tinlarebant (LBS-008), Gildeuretinol (ALK-001), Elamipretide, OCU-410, and other pipeline candidates.
*
Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
*
Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.
Table of Contents
*
Introduction
*
Executive Summary
*
Dry Age-Related Macular Degeneration: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Dry Age-Related Macular Degeneration - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Dry Age-Related Macular Degeneration Key Companies
*
Dry Age-Related Macular Degeneration Key Products
*
Dry Age-Related Macular Degeneration Unmet Needs
*
Dry Age-Related Macular Degeneration Market Drivers and Barriers
*
Dry Age-Related Macular Degeneration Future Perspectives and Conclusion
*
Dry Age-Related Macular Degeneration Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dry-agerelated-macular-degeneration-pipeline-grows-as-70-pharma-companies-advance-novel-therapies-for-vision-loss-finds-delveinsight-belite-bio-stealth-biotherapeutics-ocugen-alkeus]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus here
News-ID: 4497698 • Views: …
More Releases from ABNewswire
Pre-Eclampsia Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Dru …
DelveInsight's, "Pre-Eclampsia Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pre-Eclampsia pipeline landscape. It covers the Pre-Eclampsia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pre-Eclampsia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Pre-Eclampsia Pipeline? @…
Parkinson's Disease Clinical Trial Pipeline Gains Momentum: 150+ Companies Lead …
DelveInsight's, "Parkinson's Disease Pipeline Insight 2026" report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Parkinson's…
Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapi …
Key Asthma Companies include Generate Biomedicines, AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Pfizer, Sanofi, Amgen, and others
The global asthma therapeutic landscape is undergoing a profound transformation, driven by an expanding pipeline of innovative therapies and increased investment from leading pharmaceutical and biotechnology companies. Organizations such as Generate:Biomedicines, AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Pfizer, Sanofi, Amgen, and others are actively redefining asthma care through robust research and development…
Hyperoxaluria Pipeline Set for Breakthrough Innovation by 2026 with Advancements …
Key Hyperoxaluria Companies include Arbor Biotechnologies, META Pharmaceuticals, Biocodex, and many more
The Hyperoxaluria therapeutic landscape is witnessing a transformative shift, driven by cutting-edge research and the emergence of targeted therapies aimed at addressing the root causes of oxalate overproduction. Companies such as Arbor Biotechnologies, META Pharmaceuticals, and Biocodex are at the forefront of innovation, leveraging advanced technologies including gene editing and metabolic modulation to reshape treatment paradigms.
DelveInsight's, "Hyperoxaluria Pipeline Insight,…
More Releases for Dry
Dry Fruits Mart Expands Its Premium Dry Fruits and Organic Products Line Across …
Dry Fruits Mart has officially announced the nationwide expansion of its premium dry fruits and organic product line across Pakistan, responding to the growing demand for high-quality, natural, and nutrient-rich food products. The expansion reflects the brand's continued growth and commitment to serving customers who prioritize healthier lifestyle choices.
More information about the company and its complete product portfolio is available at: https://dryfruitsmart.pk/
As part of this development, the company has…
Rising Prevalence Of Dry Eye Conditions Boosts Growth In Dry Eye Products Market …
The Dry Eye Products Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Dry Eye Products Market Size During the Forecast Period?
In recent years, there has been a significant expansion in the market size of dry eye products. The market is projected…
Dry Powder Inhalers Market - Breathe Freely: Dry Powder Inhalers Empowering Asth …
Newark, New Castle, USA: The "Dry Powder Inhalers Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dry Powder Inhalers Market: https://www.growthplusreports.com/report/dry-powder-inhalers-market/8762
This latest report researches the industry structure,…
Dry Eye Market - Advancing Eye Wellness: Dry Eye Solutions Revolutionizing Relie …
Newark, New Castle, USA - new report, titled Dry Eye Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Dry Eye market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Dry Eye market. The report offers an overview of the market, which…
Dry Lubricants Market Size to Hit $ 813.78 Million by 2028 | Dry Lubricants Indu …
According to our experience research team, Dry Lubricants Market was valued at USD 755.42 Million in 2021, and the global Dry Lubricants industry is projected to reach a value of USD 813.78 Million by 2028, at a CAGR of 1.2% during the forecast period 2022-2028
The report is focused on gaining various Dry Lubricants market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining the market growth. Further, the global…
Dry Ice Market In-Depth Analysis | Key Participants Dry Ice Corp., Dry Ice UK Lt …
Demand for dry ice is expected to magnify with the development of dry ice machines industry across the globe. Manufacturers in large multinational organizations and private firms have been contributing prominently in the revenue growth of dry ice market. Dry ice being a cost-effective product is expected to bolster its demand across various applications in the near future. Rising number of fire accidents leads to increasing demand for dry ice,…
